Revenue-generated early access programmes in rare diseases

Our client needed help achieving early access for their rare disease product. They sought to drive early revenue across European markets to meet investor commitments, but had no experience of early access and were unsure if this could be achieved. The client also had very limited field-based resources, so needed a partner who could carry out feasibility research and help them to roll out associated projects.

The Initiate team conducted a thorough feasibility assessment to identify countries where legislation enabled early reimbursement. The team studied markers with suitable schemes in detail and presented the client with various options for advancement. We progressed the project in 12 European markets, carrying out registrations, negotiating with payers, and ultimately securing early access and revenue for the client’s project.

The client successfully generated revenue through early access while also ensuring patients were treated as soon as possible. Our approach allowed the client to achieve full reimbursement significantly quicker than they otherwise would have, accelerating the process by 6-12 months in some cases.